In yesterday’s Wall Street session, Coherus Biosciences Inc (NASDAQ:CHRS) shares traded at $2.18, up 3.32% from the previous session.
As of this writing, 9 analysts cover Coherus Biosciences Inc (NASDAQ:CHRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $4.00, we find $11.50. Given the previous closing price of $2.11, this indicates a potential upside of 445.02 percent. CHRS stock price is now -29.91% away from the 50-day moving average and -56.60% away from the 200-day moving average. The market capitalization of the company currently stands at $242.76M.
There are 3 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $10.63 as their price target over the next twelve months.
With the price target of $11, Robert W. Baird recently initiated with Outperform rating for Coherus Biosciences Inc (NASDAQ: CHRS).
In other news, Lanfear Dennis M, President & CEO sold 223,100 shares of the company’s stock on Nov 22. The stock was sold for $449,770 at an average price of $2.02. Upon completion of the transaction, the President & CEO now directly owns 731,693 shares in the company, valued at $1.6 million. Insiders disposed of 56,868 shares of company stock worth roughly $0.12 million over the past 1 year. A total of 4.66% of the company’s stock is owned by insiders.
Wednesday morning saw Coherus Biosciences Inc (NASDAQ: CHRS) opened at $2.1500. During the past 12 months, Coherus Biosciences Inc has had a low of $1.43 and a high of $10.99. The fifty day moving average price for CHRS is $3.1105 and a two-hundred day moving average price translates $5.0227 for the stock.
The latest earnings results from Coherus Biosciences Inc (NASDAQ: CHRS) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.41, missing analysts’ expectations of -$0.27 by -0.14. This compares to -$1.11 EPS in the same period last year. The net profit margin was -102.86% and return on equity was -1657.06% for CHRS. The company reported revenue of $74.57 million for the quarter, compared to $45.42 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 64.16 percent. For the current quarter, analysts expect CHRS to generate $88.24M in revenue.
Coherus Biosciences Inc(CHRS) Company Profile
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
